

Prof. Dr. Hartmut Döhner

Dr. H. Döhner is a Professor of Medicine, since 1999 he is Medical Director of the Department of Internal Medicine III (Hematology, Oncology, Palliative Medicine, Rheumatology, and Infectious Diseases) of Ulm University Hospital, 2006-2021 Director of the Comprehensive Cancer Center Ulm (since July 2021 Deputy Director), since 2020 member of the Scientific Steering Committee of the National Center for Tumor Diseases (NCT), since 2023 Deputy Director, National Center of Tumor Diseases SouthWest (NCT-SW), and since 2012 Coordinating Investigator of the Collaborative Research Center SFB 1074 “Experimental Models and Clinical Translation in Leukemia”.

Dr. Döhner studied Medicine at the Universities of Regensburg, Freiburg, and Montpellier (France). He received his training in Hematology and Medical Oncology at the University of Heidelberg (Prof. Dr. W. Hunstein). Between 1988 and 1990, he spent a two-year period as a post-doctoral associate in the Department of Medicine, Division of Oncology (Prof. Clara D. Bloomfield), and the Department of Laboratory Medicine and Pathology, Division of Medical Genetics (Prof. Diane C. Arthur), University of Minnesota, Minneapolis, USA.

Dr. Döhner is an expert in the conduct of clinical trials and in the identification, characterization and clinical diagnosis of genetic changes in hematologic malignancies, including both acute and chronic leukemias. Dr. Döhner is chairman of the German-Austrian AML Study Group (AMLSG). His Department harbors the genetic reference laboratory for several multicenter trial groups, including the AMLSG, the German Study Group for Myeloproliferative Neoplasms (GSG-MPN), the German CLL Study Group (DCLLSG), and the German Study Group for Multiple Myeloma (DSMM).

Dr. Döhner holds and was holding multiple leadership positions in the scientific community of hematology/oncology including Member of the Executive Board of the European Hematology Association (EHA) (2007-2011); Member of the Hinterzartener Kreis für Krebsforschung, Deutsche Forschungsgemeinschaft (2008-2012); Member of the Clinical Advisory Committee of the WHO Classification of Hematopoietic and Lymphoid Neoplasms 2008 and 2016; Member of the Myeloid Neoplasia Committee of the American Society of Hematology (2011-2014); Member of the Advisory Committee of the International Working Group in CLL (IWCLL); Member of the Nomination Committee of the European Hematology Association (EHA) (2014-2018); Member of the Committee “Klinische Forschung, kliniknahe Grundlagenforschung” of the Deutsche Krebshilfe (2015-2018); Member of the Scientific Committee, European School of Haematology (ESH) (2018-2020); Member of the American Society of Hematology (ASH) Award Committee (2022-2025).

In 2012, H. Döhner was elected Member of the Berlin-Brandenburg Academy of Sciences and Humanities; he is the recipient of the 2014 José Carreras Award of the European Hematology Association, one of the most prestigious awards in European hematology, and of the Johann-Georg-Zimmermann-Medaille 2020/2021 for Cancer Research; since 2014, H. Döhner is ranked among the top 1% of researchers for most cited documents, in their specific field (Thomson Reuters Highly Cited Researcher Statistics). [June 2024]

Current Positions:

- Medical Director, Department of Internal Medicine III (Hematology, Oncology, Palliative Medicine, Rheumatology, and Infectious Diseases), University Hospital Ulm, Ulm, Germany
 - Deputy Director, National Center of Tumor Diseases SouthWest (NCT-SW)
 - Member, Scientific Steering Committee, National Center of Tumor Diseases (NCT)
 - Deputy Director, Comprehensive Cancer Center Ulm (CCCU)
 - Coordinating Investigator, Collaborative Research Center (SFB) 1074 ‘Experimental models and clinical translation in leukemia’
-

Place of Birth: Bad Kreuznach, Germany

University Education:
1976-1977 University of Regensburg Medical School, Regensburg, Germany
1977-1979 University of Freiburg Medical School, Freiburg, Germany
1979-1980 One-year scholarship at the University of Montpellier Medical School, Montpellier, France
1980-1983 University of Freiburg Medical School, Freiburg

Degrees:
1985 *Doctor of Medicine*, University of Freiburg Medical School, Freiburg, Germany
1994 *Private Dozent (Habilitation)*, University of Heidelberg Medical School, Heidelberg, Germany
1999 *Professor of Medicine*, University of Ulm

Board Certification
1993 Internal Medicine
1998 Hematology and Oncology

Professional Experience:
1983-1985 Residency in Surgical Pathology, Institute of Pathology, St. Vincentius-Krankenhäuser (Prof. H.M. Schneider, Dr. H. Wolfmüller), Karlsruhe, Germany
1985-1988 Training in Internal Medicine / Hematology/Oncology, Medizinische Klinik and Poliklinik V (Prof. W. Hunstein), University of Heidelberg, Germany
1988-1990 Postdoctoral Associate in the Department of Medicine, Division of Oncology (Prof. Clara D. Bloomfield), and the Department of Laboratory Medicine and Pathology, Division of Medical Genetics (Prof. Diane C. Arthur), University of Minnesota, Minneapolis, MN, USA
1990-1993 Training in Internal Medicine / Hematology/Oncology, Medizinische Klinik and Poliklinik V (Prof. W. Hunstein), University of Heidelberg, Germany
1993-1999 *Oberarzt*, Division of Hematology/Oncology and Rheumatology; Department of Medicine (Director Prof. Dr. W. Hunstein; since 1997: Prof. A.D. Ho), University of Heidelberg, Heidelberg, Germany
2003-2011 Director, Department of Medicine, University Hospital Ulm
Since 1999 Medical Director, Department of Internal Medicine III, University of Ulm Medical Center
Since 2006 Director, Comprehensive Cancer Center Ulm (CCCU)
Since 2012 Coordinator, Collaborative Research Center (SFB) 1074 'Experimental models and clinical translation in leukemia'
2014-2015 Vice President for Medicine and Diversity, Ulm University
2018-2020 Director, Department of Medicine, University Hospital Ulm
Since 2021 Member, Scientific Executive Board, National Center of Tumor Diseases (NCT)
Since 2013 Deputy Director, National Center for Tumor Diseases SouthWest (NCT-SW)
Since 2024 Member, Board of Trustees, HARMONY Foundation

Memberships

1993	American Society of Hematology
1996	German Society of Hematology/Oncology
2001	European Hematology Association
2002	American Society of Clinical Oncology
2006	Deutsche Krebsgesellschaft

Awards

1979-80	Scholar, Deutscher Akademischer Austauschdienst
1988-90	Research Scholar, Mildred Scheel Stiftung
1995	Leukemia Clinical Research Award of the German Society of Hematology/Oncology
2009	Recipient of the Kenneth McCredie Lectureship, International Association for Comparative Research on Leukemia and Related Disorders (IACRLRD), Ohio, USA
2010	Anita- and Cuno-Wieland Research Award for Translational Cancer Research, University of Heidelberg
2011	Wilhelm-Warner Award for Cancer Research, Hamburg
2012	Elected member, Berlin-Brandenburg Academy of Sciences and Humanities
2014	José Carreras Award of the European Hematology Association (EHA)
2019	Medal of the Polish Society of Haematologists and Transfusiologists in acknowledgement of his special merit in the field of international haematology and his significant contribution to the development of this science
2019	Binet-Rai Medal of the International Workshop of Chronic Lymphocytic Leukemia in acknowledgement of his outstanding scientific achievements in CLL research
2021	Johann-Georg-Zimmermann-Medaille 2020/2021 for Cancer Research
2021	Yohei Ito Memorial Lecture, XXX IACRLRD Smposium “Precision Medicine in AML”. Beirut, Libanon
2022	David Grimwade Memorial Lecture at the 4th UK NCRI AML Academy: “The International Consensus Classification and 2022 ELN recommendations”. Birmingham, UK
Since 2014	Clarivate Web of Science Highly Cited Researcher – In recognition of ranking among the top 1% of researchers for most cited documents, in their specific field

Review for Journals and Organisations

- Annals of Hematology
- Blood
- European Journal of Immunology
- Genes Chromosomes and Cancer
- Haematologica/The Hematology Journal
- International Journal of Cancer
- Journal of Clinical Oncology
- Lancet
- Leukemia
- New England Journal of Medicine

- Associazione Italiana per la Ricerca sul Cancro
- Boehringer Ingelheim Foundation
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- Elke Kröner Fresenius Stiftung
- German-Israeli Foundation for Scientific Research and Development
- Medical Research Council, London, England
- Wilhelm-Sander Stiftung

Board / Committee Member

- Comprehensive Cancer Center Ulm (CCCU)
- Kompetenznetz “Acute and Chronic Leukemias”
- Scientific Committee of the *International Workshop of Chronic Lymphocytic Leukemia (IWCLL)*
- Elected Member (2004-2008), “Fachkollegium Medizin”, Deutsche Forschungsgemeinschaft
- Member, Leukemia Correlative Science Committee, Cancer and Leukemia Group B (CALGB), since 2006
- Member, Clinical Advisory Committee, WHO Classification of Hematopoietic and Lymphoid Neoplasms 2008
- Project Leader, Educational Committee, European Hematology Association (2005-2008)
- Member, Board (2003-2007), European Hematology Association (EHA)
- Member, Executive Board (2007-2012), European Hematology Association (EHA)
- Member, Hinterzartener Kreis für Krebsforschung, DFG (2008-2012)
- Elected Member, World Committee, International Association for Comparative Research on Leukemia and Related Disorders (IACRLRD) (2009-2013)
- Board of Directors, On-line Master Program “Advanced Oncology”, Ulm University
- Elected Member, Myeloid Neoplasia Committee, American Society of Hematology (2010-2013)
- Scientific Advisory Board, Center for Hematology and Regenerative Medicine (HERM), Karolinska Institute, Stockholm (since 2011)
- Appointed member, Haematology Working Group, Topic Advisory Group (TAG) for Internal Medicine, International Classification of Diseases (ICD), 11th edition (2011)
- Member of Advisory Board, Comprehensive Cancer Center Düsseldorf (since 2013)
- Member, Clinical Advisory Committee, WHO Classification of Hematopoietic and Lymphoid Neoplasms 2014
- Member, Nomination Committee, European Hematology Association (EHA)
- Member, Committee ‘Klinische Forschung, kliniknahe Grundlagenforschung’, Deutsche Krebshilfe (2014-2018)
- Member, Scientific Committee of the European School of Haematology (ESH) (2018-2020)
- Member, Scientific Advisory Board, Center for Cancer Research of Marseille (CRCM) and Institut Paoli-Calmettes (IPC), Marseille, France (since 2019)

Invited Faculty (Selected International Meetings, since 2015)

- Acute Leukemias XV – Biology and Treatment Strategies: Molecularly Targeted Therapies – Strategies of the AMLSG. Munich, February 22-25, 2015
- Acute Leukemias XV – Biology and Treatment Strategies: Molecularly Targeted Therapies – Strategies of the AMLSG. Munich, February 22-25, 2015
- AML & MM 2015: Akute Myeloische Leukämie – Zukünftige Entwicklungen und aktuelle Studien. Graz, February 27, 2015
- L’Ematologia Nell’Era Post-Genomica: La Medicina Di Precisione: Genomic application in the clinic: acute myeloid leukemia. Pavia, Italy, 23. May 2015
- 20th Congress of the European Hematology Association, Haematologica Celebration Session: ‘Translating Molecular Genetics of AML into Clinical Care’. Vienna, 13th June 2015

- ESH International Conference on Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment. Budapest: “Treatment of older patients considered not suitable for intensive chemotherapy.” Hungary, September 2015
- Leukemia & Lymphoma 2015: “Genomics in AML. Contributions to understanding Biology and Designing Therapy”. Dubrovnik, Croatia, September 23-25 2015.
- IV Eurasian Hematology Forum: “Molecular Genetics Guiding Treatment of Acute Myeloid Leukemia”. St. Petersburg, March 4, 2016.
- Hematological Malignancies: From Mechanisms to Therapy Symposium: “Translating Molecular Genetics of AML into Clinical Care”. Institute of European Oncology, Milano, March 10, 2016.
- 36^e Congrès de la Société Française d’Hématologie: “Prognostic Molecular Markers in AML”. Paris, March 24, 2016.
- New Drugs in Hematology: “Acute Myeloid Leukemia – State of the Art of Treatment”. Bologna, May 9-11, 2016.
- 2nd International Conference Clinical and Experimental Hematology: “Clinical trial design based on molecular heterogeneity of AML”. Kazimierz Dolny, Poland, May 20-22, 2016.
- QOL-One MDS and AML Meetings: “Molecular genetics guiding treatment of AML”. Reggio Calabria, Italy, September 16-18, 2016.
- Vidaza AML Launch meeting: „AZA AML 001: International phase 3 study of azacitidine vs conventional care regimens”. Madrid, Spain, October 1, 2016.
- Joint Symposium of the Spanish Society of Hematology (SEHH) and European Hematology Association (EHA): „Unsolved questions to be addressed by European clinical trials in in AML“. Santiago de Compostela, Spain, October 22, 2016.
- Acute Leukemias XVI Meeting: “Risk-adapted therapy of AML – AMLSG trials.” Munich, February 19-21 2017.
- ESH Training Course on WHO Classification: “Genotype-tailored therapy of AML”. Dublin, Ireland, March 9-11, 2017.
- Spring Meeting of the Austrian Society of Hematology and Medical Oncology (OeGHO): “Classification and risk stratification of AML”. Bregenz, Austria, April 6-8, 2017.
- 41st Catalan Society of Hematology Annual Symposium: “New therapeutic strategies towards molecular targets in AML: logistics and results”. Barcelona, Spain, June 2, 2017.
- 22nd Congress of the European Hematology Association: Novartis Satellite Symposium: “Current recommendations for genetic testing in AML”. Madrid, Spain, June 22-25, 2017.
- 22nd Congress of the European Hematology Association: Abbvie Satellite Symposium: “Efficacy and safety of AML therapy: Current recommendations for diagnosis and management”. Madrid, Spain, June 22-25, 2017.
- Personalized treatment strategies on myeloid neoplasms: “2017 ELN recommendations for AML.” Milano, Italy, September 25-26, 2017.
- Actualización en el Tratamiento de la Leucemia Aguda: „New treatment strategies in younger adult patients.“ Madrid, September 28-30, 2017.
- XXVIII Symposium of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD): “Molecular targets in AML”. Houston, October 30 – November 1, 2017.
- 59th Meeting of the American Society of Hematology (ASH), AML Satellite Symposium “Targeting with FLT3 Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia”: “German-Austrian AML Study Group experience with FLT3 inhibitors in AML”. Atlanta, December 8-12, 2017.
- 7th Annual Symposium on Hematological Malignancies (Critical Reviews) | Saudi Arabia: “AML 2018: State of the Art” and “The Emerging Role of Novel Therapies for AML”. Riyadh, Saudi Arabia, March 3, 2018.

- BFM Plenary Meeting: Keynote Lecture “Diagnostics and therapy of AML in adults – State-of-the-Art 2018”. Ulm, March 23, 2018.
- Personalized therapies in myeloid neoplasms: “Personalised approach to AML”. Milano, May 3, 2018.
- Meet the Expert: “Factors with prognostic impact in elderly patients with AML and how to improve the outcome”. Madrid, May 30, 2018.
- 23rd Congress of the European Hematology Association: “Molecular characterization as a basis for novel treatment paradigms in AML”. Stockholm, June 17, 2018.
- Karolinska Hematology Seminar XVI: “Acute myeloid leukemia: an update”. Rånäs Castle, Norrtälje, Sweden, September 13-14, 2018.
- Actualización en el Tratamiento de la Leucemia Aguda: “Targeted agents in AML”, “The AMLSG experience with FLT3 inhibitors”. Madrid, Spain, September 28-29, 2018.
- The 80th Annual Meeting of Japanese Society of Hematology: “Molecular targeted therapy of acute myeloid leukemia “. Osaka, Japan, October 12, 2018.
- Singapore General Hospital and National University Hospital Singapore: “Overview of AML management landscape”. Singapore, January 31-February 1, 2019.
- Acute Leukemia XVII (ISALXVII) – Biology and Treatment Strategies: “Molecular Targeted Therapies in AMLSG Portfolio”. Munich, February 25, 2019.
- 7th International Congress on Leukemia Lymphoma Myeloma: “AML Treatment Beyond 3+7”. Istanbul, Turkey, May 2-4, 2019.
- VI Eurasian Hematology Forum: “Molecular genetics guiding treatment of AML”. Moscow, Russian Federation, May 17-19, 2019.
- 28th Congress of the Polish Society of Haematology and Transfusion Medicine: “Molecular Background of AML”. Łódź, Poland, September 12-14, 2019
- QOL-One IV Annual Hematology Conference: “AML beyond ‘3+7’”. Reggio Calabria, September 18-20, 2019
- Scientific chair, ESH 5th International Conference on AML "Molecular and Translational": Advances in Biology and Treatment. Estoril, Portugal, October 24-26, 2019
- 2020 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation and The Hematology Society of Taiwan: “Evolving Treatment Landscape of AML with FLT3 Mutations”: Virtual, August 1, 2020.
- 8th International Congress on Leukemia-Lymphoma-Myeloma (virtual), Turkish Society of Hematology: “Combining new agents with „7+3“ chemotherapy in fit patients with AML”. May 21-22, 2021.
- XXX IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases) Symposium (hybrid): Yohei Ito Memorial Lecture “Precision Medicine in AML”. Beirut, Libanon, October 13-16, 2021.
- 2022 Korean Society of Hematology (KSH) International Conference & 64th Annual Meeting (ICKSH 2022): “Toward precision medicine in AML”. Seoul, Korea; April 1st, 2022 (virtual).
- Bloomfield and de la Chapelle Memorial Event: “Obituary to Prof. Clara D. Bloomfield”. Columbus, Ohio, US, June 1st, 2022.
- 27th Congress of the European Hematology Association (EHA): “Validated prognostic and therapeutic targets – in the light of the 2022 ELN recommendations”. Vienna, June 9-12, 2022.
- Acute Leukemia Masterclass: “International Consensus Classification & 2022 European LeukemiaNet recommendation for AML”; “How to treat IDH1-mutant AML at diagnosis?”; “Innovative treatment for relapsed AML”. Dubai, June 25, 2022.
- QOL-ONE V Annual Conference: “International Consensus Classification and 2022 ELN recommendations of AML”. Reggio, Calabria, Italy; July 8, 2022.

- 4th UK NCRI AML Academy: David Grimwade Memorial Lecture “The International Consensus Classification and 2022 ELN recommendations”. Birmingham, UK; September 23, 2022.
- LXIV Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia (SEHH): “2022 ELN recommendations for AML – Update of genetic risk classification”. Barcelona, Spain; October 6, 2022.
- 11th MDAnderson Leukemia Meeting: “The International Consensus Classification and 2022 ELN recommendations of AML”; “Targeting IDH mutations in AML” (virtual). Madrid, Spain; October 28-29, 2022.
- Princess Margaret Cancer Centre Leukemia Update: “The International Consensus Classification and 2022 ELN recommendations of AML”. Virtual Meeting; November 4, 2022.
- 50th anniversary of the Centre de Recherche en Cancérologie de Marseille (CRCM): “Molecular genetics of AML”. Marseille, France; November 17, 2022.
- Best of ASH Meeting: “Acute Myeloid Leukemia”. Kuwait, January 14, 2023.
- Annual Meeting of the Swedish AML Group: “ELN 2022 recommendations and beyond”. Sigtuna, Sweden, January 20, 2023.
- Essence of ASH & 46. Annual Conference of Mumbai Hematology Group: “The International Consensus Classification and 2022 ELN recommendations”; “Combining new agents with „7+3“chemotherapy in AML”; “Targeted therapies for older AML patients”. Mumbai, India, January 26-28, 2023.
- Congress of the Hematology Society of Taiwan (HST) and the Taiwan Society of Blood and Marrow Transplantation (TSBMT) - EHA-HST Joint Symposium: „Clinical impact of the new International Consensus Classification and ELN Recommendations for AML”. Taipei, Taiwan, April 12-16, 2023.
- Primeras Jornadas Integradas de la Unidad Académica de Hematología: “New International Consensus Classification and 2022 ELN recommendations for AML”. Montevideo, Uruguay, April 20-21, 2023.
- Reunión Annual CETLAM: “Clinical Impact of New Classification(s) and 2022 ELN Recommendations in AML”. Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, May 18, 2023.
- Annual Congress of the European Hematology Association: Session on “Latest updates in the ELN recommendations and the classification of AML”; presentation on “ELN recommendations 2022 and beyond (genetic risk stratification, MRD/up-date, genetic landscape in older AML patients”. Frankfurt, Germany, June 11, 2023.
- Congresso QOL-ONE: Aggiornamenti dall'EHA 2023 Convegno Regionale SIES Delegazione Calabria-Basilicata: „AML in the older patients - new developments“. Reggio Calabria, Italy, July 6-7, 2023.
- “New classification of AML and 2022 ELN genetic risk stratification”. Nanjing Jinling Hotel, Nanjing, China, July 13, 2023.
- Hematology Institute, Chinese Academy of Medicine: “New criteria for AML diagnosis and risk stratification + AMLSG recent work”. Tianjin, China, July 14, 2023., Nanjing, China, July 13, 2023.
- Tianjin Hematology Forum Summit: “Development of AML target treatment”. Shangria-la, Tianjin, China, July 14, 2023.
- Tianjin Hematology Conference: “New criteria for AML diagnosis and risk stratification”. Shangria-la, Tianjin, China, July 15, 2023.
- Peiking People’ Hospital: “Development of AML target treatment + MRD management before/after transplantation for AML patients”. Beijing, July 17, 2023.
- Shanghai City Forum: “New criteria for AML diagnosis and risk stratification + AMLSG recent work”. Intercontinental Shanghai Ruijin, Shanghai, July 18, 2023.

- The 85th Annual Meeting of the Japanese Society of Hematology (JSH), JSH-EHA Joint Symposium: “Novel landscape of AML treatment: International Consensus Classification and 2022 European LeukemiaNet (ELN) recommendations for AML”. Tokyo, October 14, 2023.
- EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms: “AML classification and risk assessment in 2023”. Budapest, November 2-4, 2023.
- Middle East Master Class in Hematology MEMAC 2024: “State of the Art Diagnosis & Therapy in Myeloid Malignancies: AML”. Dubai, January 5-6, 2024.
- PETHEMA LMA 2024: “The AMLSG Experience”. Madrid, February 2nd, 2024.
- 1st Leukemia and Lymphoma Society of Kuwait Annual Meeting: “GO or no GO: when / why / how to use GO in AML”; “How I use MRD in AML”. Kuwait, April 26-27, 2024.

Selected Publications:

2024

Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli RM, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo CD. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. **Am J Hematol**. 2024 Apr;99(4):615-624.

Roboz GJ, Sanz GF, Griffiths EA, Yee KWL, Kantarjian HM, Récher C, Byrne MT, Patkowska E, Kim HJ, Thomas X, Moors I, Stock W, Illes A, Fenaux P, Miyazaki Y, Yamauchi T, O'Connell C, Hao Y, Keer HN, Azab M, Döhner H. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial. **Blood Adv**. 2024 Apr 23;8(8):2020-2029.

2023

Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L, Lutsik P, Riedel A, Plass C, Jahn N, Walter C, Holzmann K, Hao Y, Naim S, Schreck N, Krzykalla J, Benner A, Keer HN, Azab M, Döhner K,* Döhner H.* Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. **Leukemia**. 2023 Nov;37(11):2187-2196. *Equal contribution

Huber H, Tausch E, Schneider C, Edenhofer S, von Tresckow J, Robrecht S, Giza A, Zhang C, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert ALL, Dürig J, Böttcher S, Niemann CU, Kneba M, Al-Sawaf O, Kreuzer KA, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S. Final analysis of the CLL2-GIVe trial (obinutuzumab, ibrutinib, and venetoclax) in untreated CLL with del(17p)/TP53mut. **Blood**. 2023 Sep 14;142(11):961-972.

Fenaux P, Gobbi M, Kropf P, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Urbe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva-Kyuchukova LT, Demeter J, Griffiths EA, Yee KWL, Döhner K, Hao Y, Keer HN, Azab M, Döhner H. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. **Blood Adv**. 2023 Sep 12;7(17):5027-5037

Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati S, Benner A, Schlenk, RF Döhner K, Ganser A; on behalf of the German-Austrian AML Study Group (AMLSG). Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, phase 3 trial. **Lancet Haematol**. 2023 Jul;10(7):e495-e509

Weinberg OK, Arber DA, Döhner H, Mullighan CG, Orgel E, Porwit A, Stone RM, Borowitz MJ. The International Consensus Classification of Acute Leukemias of Ambiguous Lineage. **Blood**. 2023 May 4;141(18):2275-2277.

Orazi A, Hasserjian RP, Cazzola M, Döhner H, Tefferi A, Arber DA. International Consensus Classification for Myeloid Neoplasms At-A-Glance. **Am J Hematol**. 2023 Jan;98(1):6-10.

de Botton S, Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei AH, Ommen HB, Semochkin S, Kim HJ, Larson RA, Koprivnikar J, Frankfurt O, Thol FR, Chromik J, Byrne JL, Pigneux A, Thomas X, Salamero O, Vidriales MB, Doronin VA, Döhner H, Fathi AT, Laille E, Yu X, Hasan M, Martín-Regueira P, DiNardo CD. Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloid leukemia: a randomized, phase 3 trial. **Blood**. 2023 Jan 12;141(2):156-167.

2022

Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji RS, Loh ML, Loghavi S, Mullighan CG, Ogawa S, Tefferi A, Papaemmanuil E, Reiter A, Ross DM, Savona MR, Shimamura A, Skoda RC, Sole F, Stone RM, Orazi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia. **Blood**. 2022 Nov 24;140(21):2228-2247.

Döhner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne BS, See WL, Ugidos M, Risueño A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. **Blood**. 2022 Oct 13;140(15):1674-1685

Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, Freeman S, Pradat Y, Johnson SJ, Hills R, Dillon R, Levine MF, Leongamornlert D, Butler A, Ganser A, Bullinger L, Döhner K, Ottmann O, Adams R, Döhner H, Campbell PJ, Burnett AK, Dennis M, Russell NH, Devlin SM, Huntly BJP, Papaemmanuil E. Unified classification and risk-stratification in Acute Myeloid Leukemia. **Nat Commun**. 2022;13(1):4622

Jahn N,* Jahn E,* Saadati M, Bullinger L, Larson RA, Ottone T, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Ehninger G, Heuser M, Ganser A, Pallaud C, Gathmann I, Krzykalla J, Benner A, Bloomfield CD, Thiede C, Stone RM, Döhner H, Döhner K. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. **Leukemia**. 2022 Sep;36(9):2218-222.

Döhner H, Wei AH, Appelbaum FR, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, DiNardo CD, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein E, Tallman MS, Tien HF, Wang J, Wiersbowska A, Löwenberg B. Diagnosis and management of acute myeloid leukemia in adults: 2022 recommendations from an international expert panel, on behalf of the European LeukemiaNet. **Blood**. 2022 Sep 22;140(12):1345-1377.

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes J, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey E, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Goekbuget N, Gotlib JR, Hellström-Lindberg E, Hobbs G, Hoffman R, Jabbour EJ, Kiladjan JJ, Larson RA, Le Beau MM, Loh ML, Löwenberg B, Macintyre EA, Malcovati L, Mullighan CG, Niemeyer CM, Odenike O, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer C, Schmitt-Graeff A, Shimamura A, Sierra J, Stock W, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H, Tefferi A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. **Blood**. 2022;140(11):1200-1228.

Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Novak J, Jędrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva LT, Demeter J, Griffiths EA, Yee KW, Issa JJ, Bewersdorf JPP, Keer HN, Hao Y, Azab M, Döhner H. Prospective comparison of outcomes with azacitidine and decitabine in AML patients ineligible for intensive chemotherapy. **Blood**. 2022;140(3):285-289.

Döhner H, Weber D, Krzykalla J, Fiedler W, Wulf GG, Salih HR, Lübbert M, Kühn M, Schroeder T, Salwender H, Götze KS, Westermann J, Fransecky L, Mayer K, Hertenstein B, Ringhoffer M, Tischler HJ, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik VI, Theis F, Thol FR, Heuser M, Schlenk RF, Bullinger L, Saadati M, Benner A, Larson RA, Stone RM, Döhner K, Ganser A. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. **Blood Adv**. 2022 Sep 27;6(18):5345-5355.

- Montesinos P,* Recher C,* Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, De Botton S,* Döhner H.* Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. **N Engl J Med.** 2022;386(16):1519-1531. *Equal contribution
- Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, Müller S, Popp O, Kull M, Haji M, Gütschow M, Döhner H, Walther W, Keller U, Bullinger L, Mertins P, Krönke J. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. **Nat Commun.** 2022;13(1):1009.
- Arber DA, Hasserjian RP, Orazi A, Mathews V, Roberts AW, Schiffer CA, Roug AS, Cazzola M, Döhner H, Tefferi A. Classification of myeloid neoplasms/acute leukemia: global perspectives and the International Consensus Classification (ICC) approach. **Am J Hematol.** 2022;97(5):514-518.
- Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne BS, Zhong J, Beach CL, Risueño A, Lopes de Menezes D, Ossenkoppele GJ, Döhner H. Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status. **Blood.** 2022;139(14):2145-2155.
- Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, Schneider C, Bloehdorn J, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Durig J, Böttcher S, Niemann CU, Kneba M, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S. Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia. **Blood.** 2022;139(9):1318-1329.
- Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Döhner H. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. **J Clin Oncol.** 2022;40(8):855-86.
- Estey E, Hasserjian RP, Döhner H. Distinguishing AML from MDS: A fixed blast percentage may no longer be optimal. **Blood.** 2022;139(3):323-332.
- Rücker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Döhner H, Thiede C, Döhner K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. **Leukemia.** 2022;36(1):90-99.

2021

- Döhner H, Wei A, Löwenberg B. Towards precision medicine for AML. **Nat Rev Clin Oncol.** 2021;18(9):577-590.
- DiNardo C, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Quek L, Kantarjian H, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, Döhner H. Enasidenib in combination with azacitidine versus azacitidine alone in patients with newly diagnosed mutant-IDH2 acute myeloid leukemia: a single-arm phase 1 and randomized phase 2 trial. **Lancet Oncol.** 2021;22(11):1597-16.
- Bloehdorn J, Braun A, Taylor-Weiner A, Jebaraj BMC, Robrecht S, Krzykalla J, Pan H, Giza A, Akylzhanova G, Holzmann K, Scheffold A, Johnston HE, Yeh RF, Klymenko T, Tausch E, Eichhorst B, Bullinger L, Fischer K, Weisser M, Robak T, Schneider C, Gribben J, Dahal LN, Carter MJ, Elemento O, Landau DA, Neuberger DS, Cragg MS, Benner A, Hallek M, Wu CJ, Döhner H, Stilgenbauer S, Mertens D. Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. **Nat Commun.** 2021;12(1):5395.
- Döhner H, Malcovati L, Ossenkoppele GJ, Hochhaus A, Maria Vannucchi A, Bullinger L, Cervantes F, Craddock C, de Witte T, Döhner K, Dombret H, Fenaux P, Geissler J, Germing U, Guilhot F, Harrison C, Hellström-Lindberg E, Passamonti F, Sierra J, Skoda R, Wierzbowska A. The EHA Research Roadmap: Malignant Myeloid Diseases. **Hemasphere.** 2021;5(9):e635.
- Heuser M, Heida B, Büttner K, Wienecke CP, Teich K, Funke C, Brandes M, Klement P, Liebich A, Wichmann M, Neziri B, Chaturvedi A, Kloos A, Mintzas K, Gaidzik VI, Paschka P, Bullinger L, Fiedler W, Heim A, Puppe W, Krauter J, Döhner K, Döhner H, Ganser A, Stadler M, Hambach L, Gabdoulline R, Thol F. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. **Blood Adv.** 2021;5(9):2294-2304.

- Larson RA, Mandrekar SJ, Huebner LJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Voso MT, Klisovic RB, Galinsky I, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Döhner H, Stone RM. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. **Leukemia**. 2021;35(9):2539-2551.
- Duy C, Li M, Teater M, Meydan C, Garrett-Bakelman FE, Lee TC, Chin CR, Durmaz C, Kawabata KC, Dhimolea E, Mitsiades CS, Döhner H, D'Andrea RJ, Becker MW, Paietta EM, Mason CE, Carroll M, Melnick AM. Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. **Cancer Discov**. 2021;11(6):1542-1561.
- Schmalbrock LK, Dolnik A, Cocciardi S, Sträng E, Jahn N, Panina E, Blätte TJ, Herzig J, Skambraks S, Rücker FG, Gaidzik VI, Paschka P, Fiedler W, Salih HR, Wulf G, Schroeder T, Lübbert M, Schlenk RF, Thol F, Heuser M, Larson RA, Ganser A, Stunnenberg HG, Minucci S, Stone RM, Bloomfield CD, Döhner H, Döhner K*, Bullinger L.* Clonal evolution of acute myeloid leukemia with *FLT3*-ITD mutation under treatment with midostaurin. **Blood**. 2021;137(22):3093-3104. *Equal contribution
- Feurstein S, Churpek JE, Walsh T, Keel S, Hakkarainen M, Schroeder T, Germing U, Geyh S, Heuser M, Thol F, Pohlkamp C, Haferlach T, Gao J, Owen C, Goehring G, Schlegelberger B, Verma D, Krause DS, Gao G, Cronin T, Gulsuner S, Lee M, Pritchard CC, Subramanian HP, Del Gaudio D, Li Z, Das S, Kilpivaara O, Wartiovaara-Kautto U, Wang ES, Griffiths EA, Döhner K, Döhner H, King MC, Godley LA. Germline variants drive myelodysplastic syndrome in young adults. **Leukemia**. 2021;35(8):2439-2444.
- DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, Döhner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lesch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P. Mutant IDH1 inhibitor ivosidenib in combination with azacitidine is an effective treatment for newly diagnosed acute myeloid leukemia. **J Clin Oncol**. 2021;39(1):57-65.
- Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey J, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. **Blood**. 2021;137(13):1792-1803.
- Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiarzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martínez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. **Leukemia**. 2021;35(3):835-849.

2020

- Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Cakar MK, de Sousa AB, Rybka J, Frairia C, Borin L, Beltrami G, Cermak J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Maintenance therapy with CC-486 for patients with acute myeloid leukemia in first remission after chemotherapy. **N Engl J Med**. 2020;383(26):2526-2537.
- Kapp-Schworer S, Weber D, Corbacioglu A, Gaidzik VI, Paschka P, Krönke J, Theis F, Rücker FG, Teleanu MV, Panina E, Jahn N, Herzig JK, Kubanek L, Schrade A, Gohring G, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf GG, Schleicher J, Bentz M, Krauter J, Bullinger L, Krzykalla J, Benner A, Schlenk RF, Thol F, Heuser M, Ganser A, Döhner H, Döhner K. Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial. **Blood**. 2020;136(26):3041-3050.
- Jahn N, Terzer T, Sträng E, Dolnik A, Cocciardi S, Panina E, Corbacioglu A, Herzig J, Weber D, Schrade A, Götze K, Schröder T, Lübbert M, Wellnitz D, Koller E, Schlenk RF, Gaidzik VI, Paschka P, Rücker FG, Heuser M, Thol F, Ganser A, Benner A, Döhner H, Bullinger L, Döhner K. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. **Blood Adv**. 2020;4(24):6342-6352.

- Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen YM, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Döhner K, Stone RM, Döhner H,* Bloomfield CD,* Lo-Coco F.* Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a sub-analysis from the RATIFY trial. **Blood Adv.** 2020;4(19):4945-4954. *Equal contribution
- DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai AG, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Egyed M, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Venetoclax and azacitidine combination for treatment-naïve patients with AML. **N Engl J Med.** 2020;383(7):617-629.
- Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoehstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Smedby KE, Spina V, Brusca A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillissen S, Ghielmini M, Cavalli F, Stussi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. **Blood.** 2020;135(21):1859-1869.
- Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Abou Dalle I, Döhner H, Esteve J, Floisand Y, Giebel S, Gilleece M, Gorin NC, Jabbour E, Aljurf M, Kantarjian H, Kharfan Dabaja M, Labopin M, Lanza F, Malard F, Peric Z, Prebet T, Ravandi F, Ruggeri A, Sanz J, Schmid C, Shouval R, Spyridonidis A, Versluis J, Vey N, Savani BN, Nagler A, Mohty M. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica.* 2020;105(6):1507-1516.
- Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, Bahlo J, Al-Sawaf O, Ritgen M, Fink AM, Eichhorst B, Kreuzer KA, Tandon M, Humphrey K, Jiang Y, Schary W, Bullinger L, Mertens D, Porro Lurà M, Kneba M, Döhner H, Fischer K, Hallek M, Stilgenbauer S. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. **Blood.** 2020;135(26):2402-2412.
- Döhner K,* Thiede C,* Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar S, Klisovic RB, Wei AH, Sierra J, Sanz M, Brandwein JM, de Witte T, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Benner A, Pallaud C, Stone RM,* Döhner H,* Bloomfield CD.* Impact of *NPM1/FLT3-ITD* genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. **Blood.** 2020;135(5):371-380. *Equal contribution
- Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, Heuser M, Thol F, Salih HR, Schittenhelm MM, Germing U, Kündgen A, Götze KS, Lindemann HW, Müller-Tidow C, Heil G, Scholl S, Bug G, Schwänen C, Giagounidis A, Neubauer A, Krauter J, Brugger W, De Wit M, Wäsch R, Becker H, May AM, Duyster J, Döhner K, Ganser A, Hackanson B, Döhner H. Decitabine in combination with retinoic acid and valproate in elderly acute myeloid leukemia patients. **J Clin Oncol.** 2020;38(3):257-270
- Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Samra MA, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H. Gemtuzumab ozogamicin in NPM1-mutated AML: Results from the prospective randomized AMLSG 09-09 phase-III study. **J Clin Oncol.** 2020;38(6):623-632.

2019

- Rücker FG,* Agrawal M,* Corbacioglu A,* Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group. **Blood.** 2019;134(19):1608-1618. *Equal contribution
- Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkovic K, Piccioni F, Root DE, Rücker FG, Flamand Y, Neuberg D,

Lindsley RC, Jänne PA, Hahn WC, Jacks T, Döhner H, Armstrong SA, Ebert BL. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. **Science**. 2019;365(6453):599-604.

Blätte T, Schmalbrock L, Skambraks S, Lux S, Cocciardi S, Dolnik A, Döhner H, Döhner K, Bullinger L. getITD for FLT3-ITD based MRD monitoring in AML. **Leukemia**. 2019;33(10):2535-2539.

Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rücker FG, Hirsch S, Blätte TJ, Skambraks S, Krönke J, Corbacioglu A, Gaidzik VI, Paschka P, Teleanu V, Göhring G, Thol F, Heuser M, Ganser A, Weber D, Sträng E, Kestler HA, Holzmann K, Döhner H, Bullinger L*, Döhner K.* Clonal evolution patterns in acute myeloid leukemia (AML) with NPM1 mutation. **Nat Commun**. 2019;10(1):2031

Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S. IGF1R as druggable target mediating PI3K- δ inhibitor resistance in a murine model of chronic lymphocytic leukemia. **Blood**. 2019;134(6):534-547.

Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L, Gozdecka M, Asby R, Sheppard O, Dudek M, Bullinger L, Döhner H, Dillon R, Freeman S, Ottmann O, Burnett A, Russell N, Papaemmanuil E, Hills R, Campbell P, Vassiliou GS, Huntly BJP. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. **J Exp Med**. 2019;216(4):966-981.

Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. **Blood**. 2019;133(15):1630-1643.

Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, Schroers R, Greil R, Griebßhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H. Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. **Blood**. 2019;133(8):840-851.

Close V, Close W, Kugler SJ, Reichenzeller M, Yosifov DY, Bloehdorn J, Pan L, Tausch E, Westhoff MA, Döhner H, Stilgenbauer S, Oswald F, Mertens D. FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. **Blood**. 2019;133(8):830-839.

2018

Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, Del Castillo TB, Al-Ali HK, Santini V, Vyas P, Beach CL, MacBeth KJ, Skikne BS, Songer S, Tu N, Bullinger L, Dombret H. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. **Leukemia**. 2018;32(12):2546-2557

Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, Hambach L, Stadler M, Koenecke C, Flintrop M, Pankratz M, Wichmann M, Neziri B, Büttner K, Heida B, Klesse S, Chaturvedi A, Kloos A, Göhring G, Schlegelberger B, Gaidzik VI, Bullinger L, Fiedler W, Heim A, Hamwi I, Eder M, Krauter J, Schlenk RF, Paschka P, Döhner K, Döhner H, Ganser A, Heuser M. Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. **Blood**. 2018;132(16):1703-1713

Cortes J, Perl A, Döhner H, Kantarjian H, Martinelli G, Kovacovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman J, Baldus C, Burnett A, Krämer A, Russell N, Shah N, Smith C, Wang E, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukemia: an open-label, multicenter, phase 2 trial. **Lancet Oncol**. 2018;19(7):889-903.

Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. **Leukemia**. 2018;32(7):1621-1630.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ.

Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. **Blood**. 2018;131(25):2745-2760.

Bhayadia R, Krowiorz K, Haetscher N, Jammal R, Emmrich S, Obulkasim A, Fiedler J, Schwarzer A, Rouhi A, Heuser M, Wingert S, Bothur S, Döhner K, Mätzig T, Ng M, Reinhardt D, Döhner H, Zwaan CM, van den Heuvel Eibrink M, Heckl D, Fornerod M, Thum T, Humphries RK, Rieger MA, Kuchenbauer F,* Klusmann JH.* The endogenous tumor suppressor microRNA-193b: therapeutic and prognostic value in acute myeloid leukemia. **J Clin Oncol**. 2018; 36(10):1007-1016.

Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst HA, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk RF, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. **Leukemia**. 2018;32(1):30-37.

2017

Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. **Lancet Haematol**. 2017;4(10):e475-e486

Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. **Blood**. 2017;130(12): 1477-1480.

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. **N Engl J Med**. 2017;377(5):454-464

Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. **J Clin Oncol**. 2017;35(9):934-946.

Gerstung M,* Papaemmanuil E,* Martincorena I, Bullinger L, Gaidzik VI, Paschka P, Heuser M, Thol F, Bolli N, Ganly P, Ganser A, McDermott U, Döhner K, Schlenk RF, Döhner H,* Campbell PJ.* Precision oncology for acute myeloid leukemia using a knowledge bank approach. **Nat Genet**. 2017;49(3):332-340. *Equal contribution

Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne CH, Horst HA, Lübbert M, Ganser A, Schlenk RF, Döhner H, Döhner K, Paschka P. Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): A study of the German-Austrian AML study group (AMLSG). **Leukemia**. 2017;31(4):1012-1015.

Krönke J, Kuchenbauer F, Kull M, Teleanu V, Bullinger L, Bunjes D, Greiner A, Kolmus S, Köpff S, Schreder M, Mügge LO, Straka C, Engelhardt M, Döhner H, Einsele H, Bassermann F, Bargou R, Knop S, Langer C. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). **Leukemia**. 2017;31(6):1363-1367.

Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, Wichman M, Chaturvedi A, Fabisch J, Gaidzik VI, Paschka P, Bullinger L, Bug G, Serve H, Göhring G, Schlegelberger B, Lübbert M, Kirchner H, Wattad M, Kraemer D, Hertenstein B, Heil G, Fiedler W, Krauter J, Schlenk R, Döhner K, Döhner H, Ganser A, Heuser M. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. **Leukemia**. 2017;31(6):1286-1295.

Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S. Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. **Leukemia**. 2017;31(3):734-738.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Specchia G, Efficace F, Sborgia M, Di Bona E, Breccia M, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia

C, Pogliani EM, Fozza C, D'Arco AF, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved outcomes with retinoic acid and arsenic trioxide compared to retinoic acid and chemotherapy in non-high risk acute promyelocytic leukemia. Final Results of the Italian-German APL0406 Trial. **J Clin Oncol.** 2017;35(6):605-612.419.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of acute myeloid leukemia in adults: 2017 ELN recommendations from an international expert panel. **Blood.** 2017;129(4):424-447.

2016

Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Wattad M, Köhne CH, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Salwender H, Gaidzik VI, Schlegelberger B, Weber D, Döhner K, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. **Ann Hematol.** 2016;95(12):1931-1942.

Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne CH, Germing U, Brossart P, Horst HA, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih HR, Krauter J, Döhner H, Schlenk RF, Döhner K. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group. **Leukemia.** 2016;30(11):2248-2250

Shivarov V, Dolnik A, Lang KM, Krönke J, Kuchenbauer F, Paschka P, Gaidzik VI, Döhner H, Schlenk RF, Döhner K, Bullinger L. MicroRNA expression based outcome prediction in acute myeloid leukemia - novel insights through cross-platform integrative analyses. **Haematologica.** 2016;101(11):e454-e456.

Gaidzik VI,* Teleanu V,* Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. **Leukemia.** 2016;30(11):2160-2168. *Equal contribution

Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, Radtke I, Chao JR, Walsh MP, Song G, Andersson AK, Dang J, Dong L, Liu Y, Huether R, Cai Z, Mulder H, Wu G, Edmonson M, Rusch M, Qu C, Li Y, Vadodaria B, Wang J, Hedlund E, Cao X, Yergeau D, Nakitandwe J, Pounds SB, Shurtleff S, Fulton RS, Fulton LL, Easton J, Parganas E, Pui CH, Rubnitz JE, Ding L, Mardis ER, Wilson RK, Gruber TA, Mullighan CG, Schlenk RF, Paschka P, Döhner K, Döhner H, Bullinger L,* Zhang J,* Klco JM,* Downing JR.* The genomic landscape of core-binding factor acute myeloid leukemias. **Nat Genet.** 2016;48(12):1551-1556. *Equal contribution

Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Griebhammer M, Döhner K. Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. **Leukemia.** 2016 Nov 29. [Epub ahead of print]

Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner CM, Fischer K, Hallek M, Eichhorst B, Böttcher S. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: Comprehensive analysis of two phase III studies of the German CLL Study Group. **J Clin Oncol.** 2016 Aug 29. [Epub ahead of print]

Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne CH, Germing U, Brossart P, Horst HA, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih HR, Krauter J, Döhner H, Schlenk RF, Döhner K. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: A study of the AML study group (AMLSG). **Leukemia.** 2016;30(11):2248-2250.

Vegi NM, Klappacher J, Oswald F, Mulaw MA, Mandoli A, Thiel VN, Bamezai S, Feder K, Martens JH, Rawat VP, Mandal T, Quintanilla-Martinez L, Spiekermann K, Hiddemann W, Döhner K, Döhner H, Stunnenberg HG, Feuring-Buske M, Buske C. MEIS2 is an oncogenic partner in AML-ETO positive AML. **Cell Rep.** 2016;16(2):498-507.

- Li S,* Garrett-Bakelman FE,* Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Löwenberg B, Döhner H, Döhner K, Guzman ML, Hassane DC, Roboz GJ, Grimwade D, Valk PJ, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. **Nat Med**. 2016;22(7):792-799. *Equal contribution
- Papaemmanuil E,* Gerstung M,* Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H,* Campbell PJ.* Genomic classification and prognosis in acute myeloid leukemia. **N Engl J Med**. 2016;374(23):2209-21. *Equal contribution
- Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trnecny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. **Lancet Oncol**. 2016;17(7):928-942
- Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; other authors of the EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research – a consensus document. **Haematologica**. 2016;101(2):115-208.
- Oakes C, Seifert M, Assenov Y, Gu L, Przekopowicz M, Ruppert A, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka D, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps TJ, Mertens D, Zapatka M, Lichter P, Döhner H, Küppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C. Progressive epigenetic programming during B cell maturation is reflected in a continuum of epigenetic disease phenotypes in chronic lymphocytic leukemia. **Nat Genet**. 2016;48(3):253-64.
- Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M. Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. **Blood**. 2016;127(2):208-15.

2015

- Landau DA,* Tausch E,* Taylor-Weiner AN,* Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M,* Neuberg D,* Getz G,* Stilgenbauer S,* Wu CJ.* Mutations driving CLL and their evolution in progression and relapse. **Nature**. 2015;526(7574):525-30. *Co-first / co-senior authors
- Döhner H, Weisdorf D, Bloomfield CD. Acute myeloid leukemia. **N Engl J Med**. 2015;373:1136-52.
- Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. **Blood**. 2015;126(3):291-9.
- Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, Götze K, Weber D, Göhring G, Teleanu V, Thol F, Heuder M, Döhner K, Ganser A, Döhner H, Schlenk RF. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukemia and activating FLT3 mutations. **Br J Haematol**. 2015;169(5):694-700.
- Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study of the German-Austrian Acute Myeloid Leukemia Study Group. **Haematologica**. 2015;100(3):324-30.
- Thol F, Scherr M, Kirchner A, Shahswar R, Battmer K, Kade S, Chaturvedi A, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Bug G, Ottmann O, Hofmann WK, Kröger N, Fiedler W,

Schlenk R, Döhner K, Döhner H, Krauter J, Eder M, Ganser A, Heuser M. Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. **Haematologica**. 2015;100(4):e122-4.

Gröschel S, Sanders MA, Hoogenboezem R, Zeilemaker A, Havermans M, Erpelinck C, Bindels EM, Beverloo HB, Döhner H, Löwenberg B, Döhner K, Delwel R, Valk PJ. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. **Blood**. 2015;125(1):133-9.

2014

Hoelzer D, Walewski J, Döhner H, Viardot A, Hiddemann W, Spiekermann K, Serve H, Dührsen U, Hüttmann A, Thiel E, Dengler J, Kneba M, Schaich M, Schmidt-Wolf IG, Beck J, Hertenstein B, Reichle A, Domanska-Czyz K, Fietkau R, Horst HA, Rieder H, Schwartz S, Burmeister T, Gökbuget N. **Blood**. 2014;124(26):3870-9.

Schlenk RF,* Kayser S,* Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, Lübbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Götze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Späth D, Benner A, Krauter J, Ganser A, Döhner H, Döhner K. Differential impact of allelic ratio and insertion site in *FLT3*-ITD positive AML with respect to allogeneic hematopoietic stem cell transplantation. **Blood**. 2014;124(23):3441-9. *Equal contribution

Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. **Blood**. 2014;124(9):1426-33.

Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T, Salogub GN, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Fischer K, Fink AM, Hallek M, Bloehdorn J, Busch R, Benner A, Döhner H, Valente N, Wenger MK, Stilgenbauer S, Dornan D. PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. **Blood**. 2014;124(3):420-5.

Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA Ringhoffer M, Köhne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorff A, Greil R, Heil G, Paschka P, Gaidzik VI, Göttlicher M, Döhner H, Schlanke RF. Valproic acid in combination with all-trans retinoic acid and intensive induction therapy for acute myeloid leukemia in older patients. **Blood**. 2014;123(26):4027-36.

Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. **Blood**. 2014;124(1):49-62.

Gröschel S,* Sanders MA,* Hoogenboezem R, de Wit E, Bouwman BA, Erpelinck C, van der Velden VH, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJ, Bindels EM, de Laat W, Delwel R. A single oncogenic enhancer rearrangement causes concomitant *EVI1* and *GATA2* deregulation in leukemia. **Cell**. 2014;157(2):369-81. *Equal contribution

Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. **Blood**. 123(21):3247-54.

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dillhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. **N Engl J Med**. 2014;370(12):1101-10.

Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Levenson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. **Cancer Discov**. 2014;4(3):362-75.

- Thol F, Bollin R, Gehlhaar M, Walter C, Dugas M, Suchanek KJ, Kirchner A, Huang L, Chaturvedi A, Wichmann M, Wiehlmann L, Shahswar R, Damm F, Göhring G, Schlegelberger B, Schlenk R, Döhner K, Döhner H, Krauter J, Ganser A, Heuser M. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. **Blood**. 2014;123(6):914-20.
- Wong CC, Martincorena I, Rust AG, Rashid M, Alifrangis C, Alexandrov LB, Tiffen JC, Kober C; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium, Green AR, Massie CE, Nangalia J, Lempidaki S, Döhner H, Döhner K, Bray SJ, McDermott U, Papaemmanuil E, Campbell PJ, Adams DJ. Inactivating CUX1 mutations promote tumorigenesis. **Nat Genet**. 2014;46(1):33-8.

2013

- Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch H, Munzert G, Garin-Chesa P, Fleischer F, Taube T, Döhner H. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. **Br J Haematol**. 2013;163(2):214-22.
- Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Göhring G, Kündgen A, Held G, Götze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Döhner H, Cornelissen JJ, Döhner K, Löwenberg B. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. **Blood**. 2013;122(9):1576-82.
- Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF,* Platzbecker U;* Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. **N Engl J Med**. 2013;369(2):111-21. *Equal contribution.
- Schnaiter A, Paschka P, Rossi M, Zenz T, Bühler A, Winkler D, Cazzola M, Döhner K, Edelmann J, Mertens D, Kless S, Mack S, Busch R, Hallek M, Döhner H, Stilgenbauer S. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. **Blood**. 2013;122(7):1266-70.
- Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW, Rücker FG, Holzmann K, Paschka P, Kapp-Schwörer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H, Döhner K. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. **Blood**. 2013;122(1):100-8.
- Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, Greil R, Raghavachar A, Ringhoffer M, Salih HR, Wattad M, Kirchen HG, Runde V, Heil G, Petzer AL, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu MV, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, Döhner K. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AMLSG Study Group (AMLSG). **Blood**. 2013;121(23):4769-77.
- Bullinger L, Schlenk RF, Goetz M, Botzenhardt U, Hofmann S, Russ AC, Babiak A, Zhang L, Schneider V, Döhner K, Schmitt M, Döhner H, Greiner J. PRAME induced inhibition of retinoic acid receptor signaling-mediated differentiation - a possible target for ATRA response in AML without t(15;17). **Clin Cancer Res**. 2013;19(9):2562-71.
- Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. **Blood**. 2013;121(16):3284-8.
- Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C, Fröhling S. CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPAR γ signaling. **J Clin Invest**. 2013;123(1):299-314.
- Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Späth D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Köhne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Götze K, Horst HA, Ringhoffer M, Lübbert M, Wattad M, Salih HR, Kündgen A, Döhner H, Döhner K. Secondary genetic

lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). **Blood**. 2013;121(1):170-7.

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkuppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenbergh P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H*, Delwel R.* Deregulated expression of *EVII* defines a poor prognostic subset of *MLL*-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. **J Clin Oncol**. 2013;31(1):95-103. *Equal contribution

2012

Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, Döhner K, Döhner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JR. An inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. **Cancer Cell**. 2012;22(5):683-97.

Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T, Bullinger L, Kühn MW, Gerhardinger A, Bloehdorn J, Radtke I, Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR, Stilgenbauer S, Döhner H. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. **Blood**. 2012;120(24):4783-94.

Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Krönke J, Kühn MW, Paschka P, Kayser S, Wolf S, Gaidzik VI, Schlenk RF, Rucker FG, Döhner H, Lottaz C, Döhner K, Bullinger L. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. **Blood**. 2012;120(18):e83-92.

Büchner T, Schlenk RF, Schaich M, Döhner K, Krahl R, Krauter J, Heil G, Krug U, Sauerland MC, Heinecke A, Späth D, Kramer M, Scholl S, Berdel WE, Hiddemann W, Hoelzer D, Hehlmann R, Hasford J, Hoffmann VS, Döhner H, Ehninger G, Ganser A, Niederwieser DW, Pffirmann M. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm – combined prospective analysis by the German AML Intergroup. **J Clin Oncol**. 2012;30(29):3604-10.

Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Bühler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. **J Clin Oncol**. 2012;30(26):3209-16.

Metzler KH, Heilmeier B, Edmaier KE, Rawat VP, Dufour A, Döhner K, Feuring-Buske M, Braess J, Spiekermann K, Büchner T, Sauerland MC, Döhner H, Hiddemann W, Bohlander SK, Schlenk RF, Bullinger L, Buske C. **Blood**. 2012;120(10):2118-26.

Greiner H, Ono Y, Hofmann S, Schmitt A, Mehring E, Götz M, Guillaume P, Döhner K, Mytilineos J, Döhner H, Schmitt M. Mutated regions of nucleophosmin 1 (NPM1) elicit both CD4+ and CD8+ T cell responses in patients with acute myeloid leukemia. **Blood**. 2012;120(6):1282-9.

Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JC. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. **J Clin Oncol**. 2012;30(20):2483-91.

Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, Kumar AR. EVI1 is critical for the pathogenesis of a subset of *MLL*-AF9 rearranged AMLs. **Blood**. 2012;119(24):5838-49.

Eisfeld AK, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Leffel B, Döhner H, Radmacher MD, Bloomfield CD, Tanner SM, de la Chapelle A. Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia. **Proc Natl Acad Sci U S A**. 2012;109(17):6668-73.

Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M,

Stilgenbauer S. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the GCLLSG CLL3 trial. **Blood**. 2012;119(21):4851-4859.

Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bokisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; on behalf of the German Hodgkin Study Group, the Swiss Group for Clinical Cancer Research, and the Österreichische Arbeitsgemeinschaft für Klinische Pharmakologie und Therapie. **Lancet**. 2012;379(9828):1791-9.

Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Göbele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S,* Scholl C.* Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. **J Exp Med**. 2012;209(4):697-711. *Equal contribution.

Gaidzik VI, Paschka P, Späth D, Habdank M, Köhne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döhner H, Schlenk RF, Bullinger L, Döhner K. TET2 mutations in acute myeloid leukemia (AML): Results from a comprehensive genetic and clinical analysis of the AML Study Group. **J Clin Oncol**. 2012;30(12):1350-7.

Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. **Blood**. 2012;119(18):4101-7.

Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, Kneba M. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. **J Clin Oncol**. 2012;30(9):980-8.

Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rucker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. **Cell**. 2012;148(1-2):59-71.

Kühn MW, Radtke I, Bullinger L, Goorha S, Cheng J, Edelmann J, Gohlke J, Su X, Paschka P, Pounds S, Krauter J, Ganser A, Quessar A, Ribeiro R, Gaidzik VI, Shurtleff S, Krönke J, Holzmann K, Ma J, Schlenk RF, Rubnitz JE, Döhner K, Döhner H, Downing JR. High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. **Blood**. 2012;119(10):e67-75. *Equal contribution

Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lübbert M, Fröhling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Döhner K, Döhner H. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. **Blood**. 2012;119(9):2114-21.

Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Rummel M, Germing U, Götze K, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Teleanu V, Ganser A, Döhner H, Schlenk RF. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. **Blood**. 2012;119(2):551-8.

Lübbert M, Ruter B, Claus R, Schmoor C, Schmid M, Germing U, Kündgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, heil G, Hackanson B, Deschler B, Döhner K, Hagemeyer A, Wijermans P, Döhner H. A multicenter phase II trial of Decitabine as first-line treatment of older AML patients judged unfit for induction chemotherapy. **Haematologica**. 2012;97(3):393-401.

2011

Döhner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. **Hematology Am Soc Hematol Educ Program**. 2011;2011:36-42.

Russ AC, Sander S, Luck SC, Lang KM, Bauer M, Rucker FG, Kestler HA, Schlenk RF, Döhner H, Holzmann K, Döhner K, Bullinger L. Integrative nucleophosmin mutation-associated microRNA and gene expression

pattern analysis identifies novel microRNA – target gene interactions in acute myeloid leukemia. **Haematologica**. 2011;96(12):1783-91.

Kuchenbauer F, Mah SM, Heuser M, McPherson A, Ruschmann J, Rouhi A, Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT, Karsan A, Eaves CJ, Watahiki A, Wang Y, Aparicio SA, Ganser A, Krauter J, Döhner H, Döhner K, Marra MA, Camargo FD, Palmqvist L, Buske C, Humphries RK. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. **Blood**. 2011;118(12):3350-3358.

Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K. Monitoring of minimal residual disease in *NPM1* mutated acute myeloid leukemia: A study of the German-Austrian AML Study Group (AMLSG). **J Clin Oncol**. 2011;29(19):2709-16.

Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee BH, De Silva I, Valk PJ, Delwel R, Armstrong SA, Döhner H, Gilliland DG, Huntly B. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. **Cancer Res**. 2011;71(12):4117-29.

Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Späth D, Kündgen A, Schmidt-Wolf I, Götze K, Nachbaur D, Pfreundschuh M, Horst HA, Döhner H, Döhner K. *RUNX1* mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis on 945 patients from the AML Study Group (AMLSG). **J Clin Oncol**. 2011;29(10):1364-72.

Taskesen E,* Bullinger L,* Corbacioglu A, Sanders M, Erpelinck CA, Wouters BJ, van der Poel-van de Luytgaarde S, Damm F, Krauter J, Ganser A, Schlenk RF, Lowenberg B, Delwel R, Döhner H, Valk PJ,* Döhner K.* Prognostic impact, concurrent genetic mutations and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML: further evidence for CEBPA double mutant AML as a distinctive disease entity. **Blood**. 2011;117(8):2469-75. *Equal contribution

Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H, Schlenk RF. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2,853 adult patients with newly diagnosed AML. **Blood**. 2011;117(7):2137-45.

Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. **J Clin Oncol**. 2011;29(5):475-86.

2010

Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trnety M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. **Lancet**. 2010;376(9747):1164-74.

Schlenk RF, Döhner K, Mack S, Stoppel M, Király F, Götze K, Hartmann F, Horst HA, Koller E, Petzer A, Grimminger W, Kobbe G, Glasmacher A, Salwender H, Kirchen H, Haase D, Kremers S, Matzdorff A, Benner A, Döhner H. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. **J Clin Oncol**. 2010;28(30):4642-8.

Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S. *TP53* mutation and survival in chronic lymphocytic leukemia. **J Clin Oncol**. 2010;28(29):4473-9.

Lugthart S,* Gröschel S,* Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Ossenkuppe GJ, Vellenga E, van den Berg-de Ruyter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B,* Döhner H.* Clinical, molecular, and prognostic significance of WHO type *inv(3)(q21q26.2)/t(3;3)(q21;q26.2)* and various other 3q abnormalities in acute myeloid leukemia. **J Clin Oncol**. 2010;28(24):3890-8. *Equal contribution

- Corbacioglu A,* Scholl C,* Schlenk RF, Eiwen K, Du J, Bullinger L, Fröhling S, Reimer P, Rummel M, Derigs HG, Nachbaur D, Krauter J, Ganser A, Döhner H, Döhner K. Prognostic impact of minimal residual disease in *CBFB-MYH11*-positive acute myeloid leukemia. **J Clin Oncol**. 2010;28(23):3724-9. *Equal contribution
- Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek MJ, Kneba M, Schmitz N, Stilgenbauer S. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial. **Blood**. 2010 Jul 1. [Epub ahead of print].
- Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K. *IDH1* and *IDH2* mutations are frequent genetic alterations in acute myeloid leukemia (AML) and confer adverse prognosis in cytogenetically normal AML with *NPM1* mutation without *FLT3*-ITD. **J Clin Oncol**. 2010;28(22):3636-43.
- Gröschel S,* Lugthart S,* Schlenk RF, Valk PJM, Eiwen K, Goudswaard C, van Putten WJL, Kayser S, Verdonck LF, Lübbert M, Ossenkuppe GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K,* Delwel R.* High *EVI1* expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. **J Clin Oncol**. 2010;28(12):2101-7. *Equal contribution
- Bullinger L, Ehrich M, Döhner K, Schlenk RF, Döhner H, Nelson MR, van den Boom D. Quantitative DNA-methylation predicts survival in adult acute myeloid leukemia patients. **Blood**. 2010;115(3):636-642.
- Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. **Nat Rev Cancer**. 2010;10(1):37-50.
- Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkuppe GJ, Sanz M, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an International Expert Panel, on behalf of the European LeukemiaNet. **Blood**. 2010;115(3):453-474.

2009

- Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Döhner H, Debatin KM, Stilgenbauer S, Fulda S. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. **Cancer Res**. 2009;69(23):8977-8986.
- Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S: Detailed analysis of p53 pathway defects in fludarabine-refractory CLL: dissecting the contribution of 17p deletion, *TP53* mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. **Blood**. 2009;114(13):2589-2597.
- Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J, Groner S, Späth D, Krauter J, Ganser A, Döhner H, Fischer T, Döhner K, for the German-Austrian AML Study Group (AMLSG). Insertion of *FLT3* internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. **Blood**. 2009;114(12):2386-2392.
- Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the GCLLSG. **J Clin Oncol**. 2009;27(24):3994-4001.
- Koreth J, Schlenk RF, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: a systematic review and meta-analysis of 24 prospective clinical trials. **JAMA**. 2009;301:2349-61
- Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Döhner H, Döhner K. Prognostic impact of *WT1* mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. **Blood**. 2009;113:4505-11.
- Schlenk RF,* Döhner K,* Kneba M, Götze K, Hartmann F, del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia – results from AMLSG trial AML HD98B. **Haematologica**. 2009;94:54-60. *Equal contribution.

- Madan V, Madan B, Brykczynska U, Zilbermann F, Hogeveen K, Döhner K, Döhner H, Weber O, Blum C, Rodewald HR, Sassone-Corsi P, Peters AH, Fehling HJ. Impaired function of primitive hematopoietic cells in mice lacking the mixed-lineage-leukemia homolog MLL5. **Blood**. 2009;113:1444-54.
- Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D, Winkler D, Dürig J, van Oers M, Döhner H, Stilgenbauer S. miR-34a as part of the chemotherapy resistance network in chronic lymphocytic leukemia. **Blood**. 2009;113:3801-8.
- Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Buchner T, Döhner H, Burnett AK, Lo-Coco F. Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. **Blood**. 2009;113:1875-91.

2008

- Fröhling S, Döhner H. Molecular origins of cancer: Chromosomal abnormalities in cancer. **N Engl J Med**. 2008;359:722-734.
- Bloomfield CD, Marcucci G, Döhner K, Döhner H. Acute myeloid leukemia. Introduction. **Semin Oncol**. 2008;35:324-5.
- Zenz T, Kröber A, Scherer K, Habe S, Bühler A, Benner A, Denzel T, Winkler D, Edelmann J, Schwaenen C, Döhner H, Stilgenbauer S. Mono-allelic TP53 inactivation is associated with poor prognosis in CLL: Results from a detailed genetic characterization with long term follow-up. **Blood**. 2008;112:3322-9.
- Schlenk RF,* Döhner K,* Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H,[°] for the German-Austrian AML Study Group (AMLSG). Mutations and outcome of treatment in cytogenetically normal acute myeloid leukemia. **N Engl J Med**. 2008;358:1909-18. *Equal contribution. [°]Shared senior authorship
- Bullinger L, Döhner K, Kranz R, Stirner C, Fröhling S, Scholl C, Kim YH, Schlenk RF, Tibshirani R, Döhner H,* Pollack JR*: A FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. **Blood**. 2008;111:4490-528. *Shared senior authorship.
- Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, Yu Y, Götz M, Heyduk M, Ritter G, Speiser DE, Gnjatic S, Guillaume P, Ringhoffer M, Schlenk RF, Liebisch P, Bunjes D, Shiku H, Döhner H, Greiner J. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunological and clinical responses. **Blood**. 2008;111:1357-65.
- Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Rai KR, Kipps TJ: Revised guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A Report from a Working Group sponsored by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL). **Blood**. 2008;111:5446-56.

2007

- Fröhling S,* Scholl C,* Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Döhner H, Döhner K, Ebert BL, Teckie S, Golub TR, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. **Cancer Cell**. 2007;12:501-13. *Equal contribution.
- Bullinger L, Rucker FG, Kurz S, Du J, Scholl C, Sander S, Corbacioglu A, Lottaz C, Krauter J, Fröhling S, Ganser A, Schlenk RF, Döhner K, Pollack JR,* Döhner H*: Gene expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. **Blood**. 2007;110:1291-300. *Equal contribution.
- Scholl C, Bansal D, Döhner K, Eiwien K, Huntly BJ, Lee BH, Rucker FG, Schlenk RF, Bullinger L, Döhner H, Gilliland DG, Fröhling S: The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. **J Clin Invest**. 117:1037-1048, 2007.

2006

- Estey E, Döhner H: Acute myeloid leukemia (Seminar). **Lancet**. 2006;368:1894-1907.
- Rucker FG,* Bullinger L,* Schwaenen C, Lipka DB, Wessendorf S, Fröhling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Döhner K, Döhner H: Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. **J Clin Oncol**. 2006;24:3887-3894. *Equal contribution.

2005 and earlier

- Döhner K*, Schlenk RF*, Habdank M, Scholl C, Rücker FG, Corbacioglu A, Bullinger L, Fröhling S, Döhner H: Mutant nucleophosmin (*NPM1*) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics – interaction with other gene mutations. **Blood**. 2005;106:3740-6. *Equal contribution.
- Fröhling S, Döhner H: Disruption of CEBPA function – A paradigm in myeloid leukemogenesis. **N Engl J Med**. 2004;351:2370-2372.
- Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk R, Tibshirani R, Döhner H, Pollack JR: Use of gene expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. **N Engl J Med**. 2004;350:1605-1616.
- Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K: *CEBPA* mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. **J Clin Oncol**. 2004;22:624-633. [Comment in **J Clin Oncol**. 2004;22:582-584].
- Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Döhner H, Tallman MS, Lister TA, Lo Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD: Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes and reporting standards for therapeutic trials in acute myeloid leukemia. **J Clin Oncol**. 2003;21:4642-4649.
- Scherer SW, Cheung J, MacDonald JR, ... Döhner H, Döhner K, Rommens JM, Vincent JB, Venter JC, Li PW, Mural RJ, Adams MD, Tsui LC. Human chromosome 7: DNA sequence and biology. **Science**. 2003;300:767-772.
- Stilgenbauer S, Döhner H: Campath-1H in a case of fludarabine-refractory chronic lymphocytic leukemia – Complete remission despite p53 gene mutation. **N Engl J Med**. 2002;347:452-453.
- Döhner K, Tobis K, Ulrich R, Fröhling S, Benner A, Schlenk RF, Döhner H: Prognostic significance of partial tandem duplications of the *MLL* gene in adult patients 16 to 60 years of age with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. **J Clin Oncol**. 2002;20:3254-3261.
- Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H, Stilgenbauer S: V_H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. **Blood**. 2002;100:1410-1416.
- Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P: Genomic aberrations and survival in patients with chronic lymphocytic leukemia. **N Engl J Med**. 2000;343:1910-1916.
- Stilgenbauer S,* Schaffner C,* Litterst A, Liebisch P, Gilad S, Bar-Shira A, James MR, Lichter P, Döhner H: Biallelic mutations in the *ATM* gene in T-prolymphocytic leukemia. **Nature Med**. 1997;3:1155-1159.
- Döhner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M, Fischer K, Hunstein W, Lichter P: 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. **Blood**. 1997;89:2516-2522.
- Stilgenbauer S, Liebisch P, James MR, Schröder M, Schlegelberger B, Fischer K, Bentz M, Lichter P, Döhner H: Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.2-q23.1 in lymphoproliferative disorders. **Proc Natl Acad Sci USA**. 1996;93:11837-11841.
- Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. **Blood**. 1995;85:1580-1589.